90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 42, 2015, Pages 13045-13050

  Janik, John E ^a   Morris, John C ^a   O'Mahony, Deirdre ^a   Pittaluga, Stefania ^a   Jaffe, Elaine S ^a   Redon, Christophe E ^a   Bonner, William M ^a   Brechbiel, Martin W ^a   Paik, Chang H ^b   Whatley, Millie ^b   Chen, Clara ^b   Lee, Jae Ho ^b   Fleisher, Thomas A ^b   Brown, Maggie ^b   White, Jeffrey D ^a   Stewart, Donn M ^a   Fioravanti, Suzanne ^a   Lee, Cathryn C ^a   Goldman, Carolyn K ^a   Bryant, Bonita R ^a   Junghans, Richard P ^c   Carrasquillo, Jorge A ^b   Worthy, Tat'Yana ^a   Corcoran, Erin ^a   Conlon, Kevin C ^a   Waldmann, Thomas A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

90Y daclizumab; Hodgkin's lymphoma; Myelodysplastic syndrome; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DACLIZUMAB Y 90; HISTONE H2AX; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DACLIZUMAB; IMMUNOGLOBULIN G; YTTRIUM;

ADULT; AGED; ANTIGEN EXPRESSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; ISOTOPE LABELING; KARYOTYPE; LUNG INFILTRATE; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION EXPOSURE; REED STERNBERG CELL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; CHEMISTRY; IMMUNOLOGY; MIDDLE AGED; PHOSPHORYLATION; RECURRENT DISEASE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PHOSPHORYLATION; RECURRENCE; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 84947239365     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1516107112     Document Type: Article

References (52)

1. DeVita VT, Jr, Hubbard SM (1993) Hodgkin's disease. N Engl J Med 328(8):560-565.
2. Canellos GP, et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478-1484.
3. Longo DL, et al. (1991) Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 9(8):1409-1420.
4. Diehl V, et al.; German Hodgkin's Lymphoma Study Group (2003) Standard and increased- dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348(24):2386-2395
5. dosage error in text corrected in N Engl J Med (2005) 353(7):744.
6. Schmitz N, et al.; German Hodgkin's Lymphoma Study Group; LymphomaWorking Party of the European Group for Blood and Marrow Transplantation (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359(9323):2065-2071.
7. Schnell R, Borchmann P, Schulz H, Engert A (2002) Current strategies of antibodybased treatment in Hodgkin's disease. Ann Oncol 13(Suppl 1):57-66.
8. de Claro RA, et al. (2012) U.S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18(21): 5845-5849.
9. Ansell SM, et al. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311-319.
10. Engert A, et al. (1997) A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5- SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89(2):403-410.
11. Kreitman RJ, et al. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18(8):1622-1636.
12. Younes A, et al. (2008) Objective responses in a phase I dose-escalation study of SGN- 35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 26(15S): Abstract 8526.
13. Vriesendorp HM, et al. (1991) Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 9(6):918-928.
14. Vriesendorp HM, et al. (1999) Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 5(10, Suppl):3324s-3329s.
15. Decaudin D, et al. (2007) Radioimmunotherapy (RIT) of refractory or relapsed Hodgkin's lymphoma (HL) with 90yttrium- labeled antiferritin antibody. Haematologia 92(Suppl 5): 78-79.
16. Schnell R, et al. (2005) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23(21):4669-4678.
17. Waldmann TA, et al. (1995) Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86(11):4063-4075.
18. Waldmann TA, et al. (1993) The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82(6):1701-1712.
19. Queen C, et al. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86(24):10029-10033.
20. Waldmann TA, et al. (1984) Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/ lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest 73(6):1711-1718.
21. Uchiyama T, Broder S, Waldmann TA (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126(4):1393-1397.
22. Waldmann TA, Morris JC (2006) Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 90:83-131.
23. Vincenti F, et al.; Daclizumab Triple Therapy Study Group (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338(3):161-165.
24. Agnarsson BA, Kadin ME (1989) The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissues. Cancer 63(11):2083-2087.
25. Hsu SM, Yang K, Jaffe ES (1985) Phenotypic expression of Hodgkin's and Reed- Sternberg cells in Hodgkin's disease. Am J Pathol 118(2):209-217.
26. Redon CE, et al. (2010) The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates. PLoS One 5(11):e15544.
27. Bonner WM, et al. (2008) GammaH2AX and cancer. Nat Rev Cancer 8(12):957-967.
28. Lassmann M, et al. (2010) In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 51(8):1318-1325.
29. Sedelnikova OA, Bonner WM (2006) GammaH2AX in cancer cells: A potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 5(24):2909-2913.
30. Löbrich M, et al. (2005) In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. Proc Natl Acad Sci USA 102(25):8984-8989.
31. Ekstrand BC, et al. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood 101(11):4285-4289.
32. Witzig TE, et al. (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21(7):1263-1270.
33. Press OW, et al. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329(17):1219-1224.
34. Kaminski MS, et al. (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti- B1 (anti-CD20) antibody. N Engl J Med 329(7):459-465.
35. Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 27(1):1-18.
36. Strauchen JA, Breakstone BA (1987) IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 126(3):506-512.
37. Czuczman MS, et al. (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25(27):4285-4292.
38. Bennett JM, et al. (2005) Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105(12):4576-4582.
39. Kaminski MS, et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441-449.
40. Waldmann TA, Sportes C (Protocol # NCI-12-C-0003) Clinical Trials gov. Identifier NCT01468311. Phase I/II trial of yttrium-90-labeled daclizumab (anti-CD25) radioimmunotherapy with high-dose BEAM chemotherapy and autologous hematopoietic stem cell rescue in recurrent and refractory Hodgkin's lymphoma.
41. Janik JE, et al. (2004) Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104(10):3355-3357.
42. Rubin LA, et al. (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135(5):3172-3177.
43. Brechbiel MW, Gansow OA (1992) Synthesis of C-functionalized derivatives of transcyclohexyldiethylenetriaminepenta- acetic acids for labeling of monoclonal antibodies with the bismuth -212 alpha-particle emitter. J Chem Soc, Perkin Trans 1(9):1173-1178.
44. Wu C, Gansow OA, Brechbiel MW (1999) Evaluation of methods for large scale preparation of antibody ligand conjugates. Nucl Med Biol 26(3):339-342.
45. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3(6):488-499.
46. Junghans RP, Carrasquillo JA, Waldmann TA (1998) Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies. Proc Natl Acad Sci USA 95(4):1752-1757.
47. Carrasquillo JA, et al. (1999) Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med 40(2):268-276.
48. Kroll H, et al. (1957) Excretion of yttrium and lanthanum chelates of cyclohexane 1, 2- trans diamine tetraacetic acid and diethylenetriamine pentaacetic acid in man. Nature 180(4592):919-920.
49. Loevinger R, Berman M (1976) Calculating the absorbed dose from biologically distributed radionuclides (The Society of Nuclear Medicine, New York).
50. Sgouros G (1993) Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34(4):689-694.
51. Nussenblatt RB, et al. (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc Natl Acad Sci USA 96(13):7462-7466.
52. Cheson BD, et al.; NCI Sponsored International Working Group (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17(4):1244-1253.